Thompson’s death put spotlight on unfair health insurance claim denials

The killing of UnitedHealthcare CEO Brian Thompson became a flashpoint for a debate that extends far beyond the circumstances of his death: the longstanding frustration of patients and families who say they have struggled to obtain medical care after insurance companies denied or delayed coverage.

Thompson was the sole fatal victim of the December 2024 shooting in Manhattan. His killing and the allegations surrounding the gunman are separate from the insurance disputes that followed. But Thompson’s position at the helm of UnitedHealthcare made the company—and the broader practices of the U.S. health-insurance industry—the focus of intense public discussion.

That discussion centered particularly on prior authorization, claim denials and utilization management, practices insurers use to determine whether particular treatments and services will be covered.

Patients, physicians and families have for years complained that these processes can delay care or place burdens on people who are already sick. UnitedHealthcare and other insurers, meanwhile, say such controls are necessary to prevent inappropriate treatment, fraud and unnecessary medical spending.

A controversy that predates Thompson’s death

The debate was already well established before Thompson was killed.

UnitedHealthcare requires prior authorization for certain medical services, meaning a doctor or patient must obtain approval before treatment will be covered. When authorization or a claim is denied, patients generally have mechanisms for appealing the decision.

Federal investigations have nevertheless raised concerns about how insurers administer these systems.

A 2024 Senate investigation examined UnitedHealthcare, Humana and CVS and found that the insurers had increasingly relied on prior authorization for expensive post-acute services, including skilled-nursing and rehabilitation care. For UnitedHealthcare, the Senate report said the company’s initial denial rate for post-acute-care authorization requests increased from 8.7% in 2019 to 22.7% in 2022.

The investigation also examined the company’s use of automated systems and algorithms in utilization-management decisions, raising questions about whether technology could contribute to inappropriate denials or make it harder for patients to obtain individualized reviews.

Those findings became especially significant after Thompson’s killing because public anger over insurance denials suddenly had a highly visible corporate figure attached to it.

Patients’ stories became part of the conversation

Following Thompson’s death, stories from patients and families about denied or delayed care circulated widely online and in news coverage. Some described lengthy battles with insurers over rehabilitation, medications, surgeries and other forms of treatment.

Those accounts have helped illustrate why an insurance denial can feel fundamentally different from an ordinary customer-service dispute. A denied claim can mean an unexpected medical bill, a delay in treatment or a dispute over whether a patient qualifies for a particular service.

But individual stories also require caution. A claim that an insurer denied treatment does not, by itself, establish that the denial caused a patient’s injury or death. Such conclusions require evidence about the patient’s medical circumstances and the specific insurance decision.

What UnitedHealthcare says

UnitedHealthcare has rejected broad characterizations that it routinely denies medically necessary care. The company has said that most claims are ultimately approved and paid and that many claims initially rejected for administrative reasons are resolved when additional information is provided. It has also defended prior authorization as a tool intended to ensure that treatment is appropriate and supported by medical evidence.

The company has also begun reducing the number of services subject to prior authorization. In May 2026, UnitedHealthcare announced that it was eliminating authorization requirements for 30% of services that had previously required them, saying the change was intended to simplify access to care.

The larger question

The significance of Thompson’s death in the health-insurance debate is therefore not that his killing proved that UnitedHealthcare’s practices harmed particular patients. It did not.

Instead, the killing elevated an existing controversy into a national conversation. Thompson’s role made UnitedHealthcare a symbol in a much larger argument about who ultimately decides whether a patient receives medical care: the doctor, the patient, or the insurance company paying the bill.

That argument was already generating scrutiny from Congress, regulators, doctors and patient advocates. Thompson’s death gave it an extraordinary new level of public attention.

The resulting debate has exposed a difficult distinction at the heart of American health care. Insurers argue that utilization controls are necessary to make an expensive system affordable and prevent unnecessary treatment. Patients and their advocates argue that the same mechanisms can become barriers between people and care their doctors believe they need.

Those competing claims will continue to be judged through lawsuits, government investigations, appeals and individual patient experiences. Thompson’s death did not resolve that debate. It made it much harder for the country to ignore.